But some of this political thinking is inertia, because for decades, on issues like the roll-out of generic drugs, the regulatory climate, and strong protections for intellectual property, drug companies were clearly better off with the pro-business Republican party.
But a Consumer Reports analysis found that the FDA was as likely to warn about manufacturing issues at a brand-name drug factory as a generic one, Dr. Santa says.
This pressure will manifest itself in two generic ways: First, the meeting will focus on micro level issues, where greater latitude will be sought to sell more sophisticated and, therefore more strategically significant, technologies.